초록

This invention is directed to a polymer-clay nanocomposite, products produced from the nanocomposite, and a process for preparing a polymer-clay nanocomposite. The polymer-clay nanocomposite comprises (a) a matrix polymer, (b) an amorphous oligomer, and (c) a layered clay material.

대표청구항 ▼

This invention is directed to a polymer-clay nanocomposite, products produced from the nanocomposite, and a process for preparing a polymer-clay nanocomposite. The polymer-clay nanocomposite comprises (a) a matrix polymer, (b) an amorphous oligomer, and (c) a layered clay material. n alkyl group; Ri

This invention is directed to a polymer-clay nanocomposite, products produced from the nanocomposite, and a process for preparing a polymer-clay nanocomposite. The polymer-clay nanocomposite comprises (a) a matrix polymer, (b) an amorphous oligomer, and (c) a layered clay material. n alkyl group; Ri,is a hydrogen, an alkyl, an aryl, an alkylcarboxylic acid, an aryl carboxylic acid, an alkylcarboxylic ester, an arylcarboxylic ester, an alkylcarboxamido, an arylcarboxamido, an alkylaryl, an alkylsulfinyl, an alkylsulfonyl, an arylsulfinyl, an arylsulfonyl, a sulfonamido, a carboxamido, a carboxylic ester, an amino alkyl, an amino aryl, --CH2--C(T--Q)(Re)(Rf), or --(N2O2--)-.M+,wherein M+is an organic or inorganic cation; with the proviso that when Ri,is --CH2--C(T--Q)(Re)(Rf) or --(N2O2--).M+; then "--T--Q" can be a hydrogen, an alkyl group, an alkoxyalkyl group, an aminoalkyl group, a hydroxy group or an aryl group. 6. A composition comprising at least one H2receptor antagonist compound or a pharmaceutically acceptable salt thereof, and at least one compound that induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. 7. A composition comprising at least one H2receptor antagonist compound or a pharmaceutically acceptable salt thereof, and at least one compound selected from: (i) a compound that comprises at least one ON--O-- or ON--C-- group; and (ii) a N-oxo-N-nitrosoamine having the formula: R1R2N--N(O--M+)--NO, wherein R1and R2are each independently a polypeptide, an amino acid, a sugar, an oligonucleotide, a straight or branched, saturated or unsaturated, aliphatic or aromatic, substituted or unsubstituted hydrocarbon, or a heterocyclic group, and M+is an organic or inorganic cation. 8. The composition of claim 7, wherein the compound comprising at leas one ON--O-- group or ON--C-- group is an ON--O-polypeptide, an ON--C-polypeptide, an ON--O-amino acid, an ON--C-amino acid, an ON--O-sugar, an ON--C-sugar, an ON--O-oligonucleotide, an ON--C-oligonucleotide, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON--O-hydrocarbon, a straight or branched, saturated or unsaturated, substituted or unsubstituted, aliphatic or aromatic ON--C-hydrocarbon, an ON--O-heterocyclic compound or a ON--C-heterocyclic compound. 9. The composition of claims 1, 6 or 7, further comprising at least one of a nonsteroidal antiinflammatory drug, an antacid, a bismuth-containing reagent, and an anti-viral agent. 10. A method for treating or preventing a gastrointestinal disorder, facilitating ulcer healing, or decreasing the recurrence of an ulcer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the composition of claims 1, 6 or 7. 11. The method of claim 10, further comprising administering to the patient a therapeutically effective amount of an antacid. 12. The method of claim 10, wherein the gastrointestinal disorder is a peptic ulcer, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, a stress ulcer, a bleeding peptic ulcer, short bowel syndrome, or a hypersecretory state associated with systemic mastocytosis or basophilic leukemia and hyperhistaminemia. 13. A method for improving the gastroprotective properties, the anti-Helicobacter properties, or the antacid properties of an H2receptor antagonist comprising administering to a patient in need thereof a therapeutically effective amount of the composition of claims 1, 6 or 7. 14. The method of claim 13, further comprising administering to the patient a therapeutically effective amount of a bismuth-containing reagent. 15. A method for decreasing or reversing gastrointestinal toxicity or facilitating ulcer healing resulting from administration of a nonsteroidal antiinflammatory drug to a patient comprising admini